These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30677865)

  • 21. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.
    Llobet D; Eritja N; Encinas M; Llecha N; Yeramian A; Pallares J; Sorolla A; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
    Oncogene; 2008 Apr; 27(18):2513-24. PubMed ID: 17982483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells.
    Rabalski AJ; Gyenis L; Litchfield DW
    Clin Cancer Res; 2016 Jun; 22(12):2840-7. PubMed ID: 27306791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro.
    Lawnicka H; Kowalewicz-Kulbat M; Sicinska P; Kazimierczuk Z; Grieb P; Stepien H
    Cell Tissue Res; 2010 May; 340(2):371-9. PubMed ID: 20383646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Casein kinase II inhibition induces apoptosis in pancreatic cancer cells.
    Hamacher R; Saur D; Fritsch R; Reichert M; Schmid RM; Schneider G
    Oncol Rep; 2007 Sep; 18(3):695-701. PubMed ID: 17671722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein kinase CK2 as a druggable target.
    Sarno S; Pinna LA
    Mol Biosyst; 2008 Sep; 4(9):889-94. PubMed ID: 18704226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2.
    Spinello Z; Fregnani A; Quotti Tubi L; Trentin L; Piazza F; Manni S
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of protein kinase CK2 as a key target in cancer therapy.
    Trembley JH; Chen Z; Unger G; Slaton J; Kren BT; Van Waes C; Ahmed K
    Biofactors; 2010; 36(3):187-95. PubMed ID: 20533398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salicylaldehyde derivatives as new protein kinase CK2 inhibitors.
    Prudent R; López-Ramos M; Moucadel V; Barette C; Grierson D; Mouawad L; Florent JC; Lafanechère L; Schmidt F; Cochet C
    Biochim Biophys Acta; 2008 Dec; 1780(12):1412-20. PubMed ID: 18674590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells.
    Wang G; Ahmad KA; Ahmed K
    Cancer Res; 2006 Feb; 66(4):2242-9. PubMed ID: 16489027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Casein kinases as potential therapeutic targets.
    Cozza G; Pinna LA
    Expert Opin Ther Targets; 2016; 20(3):319-40. PubMed ID: 26565594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2.
    Prudent R; Moucadel V; Nguyen CH; Barette C; Schmidt F; Florent JC; Lafanechère L; Sautel CF; Duchemin-Pelletier E; Spreux E; Filhol O; Reiser JB; Cochet C
    Cancer Res; 2010 Dec; 70(23):9865-74. PubMed ID: 21118972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repressing the activity of protein kinase CK2 releases the brakes on mitochondria-mediated apoptosis in cancer cells.
    Hanif IM; Pervaiz S
    Curr Drug Targets; 2011 Jun; 12(6):902-8. PubMed ID: 21269261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.
    Chon HJ; Bae KJ; Lee Y; Kim J
    Front Pharmacol; 2015; 6():70. PubMed ID: 25873900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effects of a Selective CK2 Inhibitor on Anti-glomerular Basement Membrane Glomerulonephritis in Rats.
    Shi J; Liu N; Xiao Y; Takei Y; Yasue M; Suzuki Y; Hou Z; Ohno H; Yamada M; Fuchi N; Oshida K; Miyamoto Y; Tsujimoto G; Hirasawa A
    Biol Pharm Bull; 2015; 38(9):1345-51. PubMed ID: 26328489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of mitoxantrone on the activity of human protein kinase CK2 holoenzyme].
    Li CM; Liu XG; Lin XC; Chen XW; Liang NC
    Ai Zheng; 2008 Aug; 27(8):809-15. PubMed ID: 18710613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mining CK2 in cancer.
    Ortega CE; Seidner Y; Dominguez I
    PLoS One; 2014; 9(12):e115609. PubMed ID: 25541719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracellular hydrogen peroxide production is an upstream event in apoptosis induced by down-regulation of casein kinase 2 in prostate cancer cells.
    Ahmad KA; Wang G; Ahmed K
    Mol Cancer Res; 2006 May; 4(5):331-8. PubMed ID: 16687488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional proteomics strategy for validation of protein kinase inhibitors reveals new targets for a TBB-derived inhibitor of protein kinase CK2.
    Gyenis L; Kuś A; Bretner M; Litchfield DW
    J Proteomics; 2013 Apr; 81():70-9. PubMed ID: 23017496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.